Methionine Synthase Reductase-A66G and -C524T Single Nucleotide Polymorphisms and Prostate Cancer: A Case-Control Trial

Abstract

Purpose: Some variations in the sequence of methionine synthase reductase (MTRR) gene can increase the risk of<br />various cancers such as prostate cancer. The aim of this study was to investigate the association between prostate cancer<br />and the MTRR A66G and C524T gene single nucleotide polymorphisms (SNPs) using an in silico analysis. Methods:<br />In this case-control study, 218 Iranian men, including 108 men with prostate cancer and 110 prostate cancer-free men,<br />were enrolled. The MTRR A66G and C524T genotyping was performed by PCR-RFLP. Some of the bioinformatics<br />tools were employed for the evaluation of polymorphism on the molecular aspects of the MTRR. Results: With regard<br />to the MTRR A66G polymorphism, the genotype AG (OR: 0.85, 95% CI: 0.47-1.54, p= 0.6014), genotype GG (OR:<br />0.89, 95% CI: 0.42-1.87, p= 0.7512), and allele G (OR: 0.92, 95% CI: 0.63-1.35, p= 0.6686) were not associated with<br />prostate cancer risk. However, the data for C524T SNP showed that the genotype CT was associated with prostate<br />cancer risk (OR: 1.92, 95% CI: 1.06-3.47, p= 0.0308). Further, carriers of the allele T (OR: 1.80, 95% CI: 1.04-3.13,<br />p= 0.0358) were associated with high risk of prostate cancer. In addition, bioinformatics analysis revealed that C524T<br />SNP could affect some molecular aspects of the protein structure, while having no effect on the mRNA structure.<br />Conclusion: The MTRR C524T is a genetic risk factor for prostate cancer; however, the MTRR A66G is not suggested<br />as a suitable biomarker for prostate cancer. To obtain more reliable results, further studies are recommended to use<br />larger sample sizes and investigate the effects of environmental factors.